摘要
目的探讨高级别浆液性卵巢癌患者中P53、人表皮生长因子受体2(CerbB-2)、雌激素受体(ER)和孕激素受体(PR)的表达情况及其与患者复发风险的关系。方法选取2002年9月—2011年2月入住本院的高级别浆液性卵巢癌患者32例,宫颈癌国际妇产科联盟(FIGO)分期Ⅲ期30例、Ⅳ期2例。以12个月为界,将患者分为无复发生存时间(RFS)≥12个月组(18例)和RFS<12个月组(14例)。采用免疫组化法检测高级别浆液性卵巢癌组织中P53、CerbB-2、ER和PR的表达情况,并分析其与高级别浆液性卵巢癌患者复发风险的关系。结果 P53、ER和PR表达主要位于细胞核,CerbB-2表达主要位于细胞膜。32例高级别浆液性卵巢癌患者中,P53、CerbB-2、ER和PR的阳性表达率分别为62.5%(20/32)、43.8%(14/32)、68.8%(22/32)和34.4%(11/32)。不同RFS的高级别浆液性卵巢癌患者P53、ER和PR的阳性表达率间差异无统计学意义(P>0.05);RFS<12个月组CerbB-2的阳性表达率高于RFS≥12个月组(P<0.05)。进一步对CerbB-2、ER和PR的共表达(以CerbB-2阴性、ER阳性或PR阴性为标准,同一个患者只要符合2个及以上标准即为共表达阳性)情况进行分析发现,RFS≥12个月组CerbB-2、ER和PR共表达阳性率高于RFS<12个月组(P<0.05)。结论联合检测CerbB-2、ER和PR可作为预测高级别浆液性卵巢癌患者复发风险的潜在标志物。
Objective To investigate the relationship of the expressions of P53, human epidermal growth factor recep- tor 2 （CerbB -2）, estrogen receptor （ER） and progesterone receptor （PR） to recurrence of high -level serous ovarian cancer （SOC）. Methods Thirty- two high -level SOC patients were divided, according to FIGO staging, into groups stages 11/ （n = 30）, IV （n = 2）. Taking 12 months as a time boundary, patients divided into groups A [ recurrence free survival （RFS） ≥ 12 months, n = 18 ], B [ RFS 〈 12 months （n = 14）]. Immunohistochemistry method was used to detect the expressions of P53, CerbB - 2, ER, PR, and their relationship to recurrence risks of high - level SOC was analyzed. Results P53, ER and PR expression was mainly located in the nucleus, CerbB -2 expression was mainly located in the cell membrane. The positive expression rates of P53, CerbB-2, ER, PR were 62. 5% （20/32） , 43.8% （14/32）, 68. 8% （22/32）, 34.4% （11/ 32）, respectively. No significant difference was noted in positive expression rates of P53, ER, PR between SOC patients at dif- ferent RFSs （P 〉 0.05 ）. CerbB - 2 positive expression rate was higher in group B than in group A （P 〈 0.05 ）, and positive coexpression rate of CerbB - 2, ER, PR higher in group A than in group B （P 〈 0. 05）. Conclusion Combined detection of CerbB - 2, ER, PR can be used as a potential biomarker predicting recurrence risks of high - level SOC.
出处
《中国全科医学》
CAS
CSCD
北大核心
2014年第2期151-154,共4页
Chinese General Practice
基金
国家自然科学基金青年科学基金项目(81202053)
浙江省自然科学基金项目(Y2080586
Y2100593)
关键词
卵巢肿瘤
复发
人表皮生长因子受体2
受体
雌激素
孕激素受体
Ovarian neoplasms
Recurrence
Human epidermal growth factor receptor 2
Receptors, estrogen
Progesterone receptor
